RU2669388C1 - Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида - Google Patents

Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида Download PDF

Info

Publication number
RU2669388C1
RU2669388C1 RU2017114501A RU2017114501A RU2669388C1 RU 2669388 C1 RU2669388 C1 RU 2669388C1 RU 2017114501 A RU2017114501 A RU 2017114501A RU 2017114501 A RU2017114501 A RU 2017114501A RU 2669388 C1 RU2669388 C1 RU 2669388C1
Authority
RU
Russia
Prior art keywords
methyl
phenyl
pyridinyl
thiazol
monohydrate
Prior art date
Application number
RU2017114501A
Other languages
English (en)
Russian (ru)
Inventor
Вильфрид ШВАБ
Александр БИРКМАНН
Курт ФЕГТЛИ
Дитер ХААГ
Андреас ЛЕНДЕР
Альфонс Груненберг
Биргит Кайль
Йоахим Резе
Original Assignee
Айкурис Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айкурис Гмбх Унд Ко. Кг filed Critical Айкурис Гмбх Унд Ко. Кг
Application granted granted Critical
Publication of RU2669388C1 publication Critical patent/RU2669388C1/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
RU2017114501A 2011-09-26 2012-09-26 Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида RU2669388C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11007823.5 2011-09-26
EP11007823A EP2573086A1 (en) 2011-09-26 2011-09-26 N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014107430A Division RU2620604C2 (ru) 2011-09-26 2012-09-26 Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида

Publications (1)

Publication Number Publication Date
RU2669388C1 true RU2669388C1 (ru) 2018-10-11

Family

ID=46889067

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017114501A RU2669388C1 (ru) 2011-09-26 2012-09-26 Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида
RU2014107430A RU2620604C2 (ru) 2011-09-26 2012-09-26 Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014107430A RU2620604C2 (ru) 2011-09-26 2012-09-26 Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида

Country Status (29)

Country Link
US (1) US9340535B2 (enExample)
EP (3) EP2573086A1 (enExample)
JP (2) JP6161614B2 (enExample)
KR (4) KR20190104249A (enExample)
CN (2) CN105541829A (enExample)
AR (3) AR088043A1 (enExample)
AU (2) AU2012314536B2 (enExample)
BR (1) BR112014003245B1 (enExample)
CA (1) CA2791142C (enExample)
CL (1) CL2014000149A1 (enExample)
DK (2) DK2598501T3 (enExample)
ES (2) ES2466221T3 (enExample)
HK (1) HK1220978A1 (enExample)
HR (1) HRP20140351T1 (enExample)
IL (2) IL230152A (enExample)
IN (1) IN2014DN01993A (enExample)
JO (2) JO3037B1 (enExample)
MX (2) MX371088B (enExample)
MY (2) MY190878A (enExample)
PE (1) PE20141148A1 (enExample)
PH (2) PH12014500567A1 (enExample)
PL (2) PL2598501T3 (enExample)
PT (1) PT2598501E (enExample)
RU (2) RU2669388C1 (enExample)
SG (1) SG10201407430TA (enExample)
TW (2) TWI567070B (enExample)
UA (2) UA115317C2 (enExample)
WO (1) WO2013045479A1 (enExample)
ZA (2) ZA201401773B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
CR20180482A (es) * 2016-04-06 2019-04-09 Innovative Molecules Gmbh Derivados de aminotiazol útiles como agentes antivíricos
PT3848369T (pt) * 2016-11-28 2023-04-10 Aicuris Gmbh & Co Kg Hemi-hidrato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricação e suas utilizações
WO2018096177A1 (en) * 2016-11-28 2018-05-31 Aicuris Anti-Infective Cures Gmbh A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses
TW201825095A (zh) * 2016-11-28 2018-07-16 德商艾庫里斯抗感染治療有限公司 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物
KR102335327B1 (ko) 2017-04-28 2021-12-03 현대자동차 주식회사 수냉식 이지알 쿨러
EP3644958B1 (en) * 2017-06-28 2021-09-29 AiCuris GmbH & Co. KG Intravaginally applicable devices comprising antiviral compounds
AR113344A1 (es) 2017-10-05 2020-04-22 Innovative Molecules Gmbh Enantiómeros de una serie de compuestos antivirales
KR102535452B1 (ko) 2018-07-06 2023-05-26 파에노 테라퓨틱스 씨오., 엘티디. 티아졸 화합물의 결정형 및 이의 응용
EP4509118A3 (en) * 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
EP4096632A1 (en) * 2020-03-26 2022-12-07 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
EP4581030A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
CN119731171A (zh) 2022-08-29 2025-03-28 组装生物科学股份有限公司 普瑞利韦的新的结晶形式
JP2025530762A (ja) 2022-08-29 2025-09-17 アセンブリー・バイオサイエンシーズ・インコーポレイテッド ヘルペスウイルス用医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047904A1 (de) * 1999-12-23 2001-07-05 Bayer Aktiengesellschaft Thiazolylamid-derivate
WO2006103011A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische zubereitung von n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
RU2422449C2 (ru) * 2004-10-25 2011-06-27 Пайрамед Лимитед Фармацевтические соединения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129716A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129717A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
JP2007314516A (ja) * 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd 2以上の置換基を有するベンゼン化合物を含有する医薬
EA201200423A1 (ru) * 2006-06-09 2012-08-30 Икос Корпорейшн Замещенные фенилуксусные кислоты как dp-2-антагонисты
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047904A1 (de) * 1999-12-23 2001-07-05 Bayer Aktiengesellschaft Thiazolylamid-derivate
RU2422449C2 (ru) * 2004-10-25 2011-06-27 Пайрамед Лимитед Фармацевтические соединения
WO2006103011A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische zubereitung von n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamid

Also Published As

Publication number Publication date
EP2602258B1 (en) 2014-03-19
ES2466221T8 (es) 2016-09-13
TWI567070B (zh) 2017-01-21
TW201625603A (zh) 2016-07-16
EP2602258A1 (en) 2013-06-12
TW201317234A (zh) 2013-05-01
EP2602258B8 (en) 2016-09-28
UA119574C2 (uk) 2019-07-10
JP6353022B2 (ja) 2018-07-04
NZ718867A (en) 2016-05-27
KR20170055565A (ko) 2017-05-19
BR112014003245B1 (pt) 2021-11-09
PL2602258T3 (pl) 2014-08-29
US20140221433A1 (en) 2014-08-07
AR088043A1 (es) 2014-05-07
JO3037B1 (ar) 2016-09-05
BR112014003245A2 (pt) 2017-03-01
MX338736B (es) 2016-04-29
CL2014000149A1 (es) 2014-09-05
EP2573086A1 (en) 2013-03-27
MX2014003389A (es) 2014-07-09
PH12015502801A1 (en) 2016-10-03
IL234405A (en) 2015-04-30
DK2602258T3 (da) 2014-04-22
AR120291A2 (es) 2022-02-09
AU2012314536A1 (en) 2014-02-06
ES2466221T3 (es) 2014-06-09
AU2015260762B2 (en) 2016-06-09
NZ621615A (en) 2016-04-29
JP2017114859A (ja) 2017-06-29
TWI532739B (zh) 2016-05-11
UA115317C2 (uk) 2017-10-25
KR20180088530A (ko) 2018-08-03
JO3734B1 (ar) 2021-01-31
EP2598501B1 (en) 2014-03-12
RU2014107430A (ru) 2015-11-10
EP2598501A1 (en) 2013-06-05
KR101768295B1 (ko) 2017-08-14
ES2462492T3 (es) 2014-05-23
DK2598501T3 (da) 2014-04-22
KR20190104249A (ko) 2019-09-06
PH12014500567A1 (en) 2014-04-14
US9340535B2 (en) 2016-05-17
MY185063A (en) 2021-04-30
HRP20140351T1 (hr) 2014-07-04
HK1220978A1 (zh) 2017-05-19
RU2620604C2 (ru) 2017-05-29
AU2015260762A1 (en) 2016-02-04
JP2014528948A (ja) 2014-10-30
PE20141148A1 (es) 2014-09-15
AU2012314536B2 (en) 2016-01-14
CN103842359B (zh) 2016-05-25
CA2791142A1 (en) 2013-03-26
IL230152A (en) 2015-04-30
PT2598501E (pt) 2014-06-25
WO2013045479A1 (en) 2013-04-04
KR20140066704A (ko) 2014-06-02
AR116394A2 (es) 2021-05-05
PH12015502801B1 (en) 2016-10-03
CA2791142C (en) 2017-08-01
CN103842359A (zh) 2014-06-04
MY190878A (en) 2022-05-13
ZA201401773B (en) 2015-12-23
MX371088B (es) 2020-01-16
JP6161614B2 (ja) 2017-07-12
SG10201407430TA (en) 2014-12-30
PL2598501T3 (pl) 2014-08-29
IN2014DN01993A (enExample) 2015-05-15
ZA201408734B (en) 2016-08-31
CN105541829A (zh) 2016-05-04

Similar Documents

Publication Publication Date Title
RU2669388C1 (ru) Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида
AU2012314473B2 (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations.
AU2003224779A1 (en) Lansoprazole polymorphs and processes for preparation thereof
CA2939529C (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
HK1196018A (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
HK1196018B (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
NZ621615B2 (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
NZ718867B2 (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
HK1196017A (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations